BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 27910026)

  • 1. Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes.
    Wall M
    Methods Mol Biol; 2017; 1541():209-222. PubMed ID: 27910026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diagnosis and prognosis in myelodysplastic syndromes. The impact of cytogenetics].
    Mecucci C
    Recenti Prog Med; 2014 Mar; 105(3):110-4. PubMed ID: 24675452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Applications of Chromosomal Microarray Testing in Myeloid Malignancies.
    Ronaghy A; Yang RK; Khoury JD; Kanagal-Shamanna R
    Curr Hematol Malig Rep; 2020 Jun; 15(3):194-202. PubMed ID: 32382988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Progress of cytogenetic detection in myelodysplastic syndromes].
    Zhou QB; Hu XM; Liu -; Ma R
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1536-40. PubMed ID: 22169320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiplex ligation-dependent probe amplification assay identifies additional copy number changes compared with R-band karyotype and provide more accuracy prognostic information in myelodysplastic syndromes.
    Wang J; Ai X; Qin T; Xu Z; Zhang Y; Liu J; Li B; Fang L; Zhang H; Pan L; Hu N; Qu S; Cai W; Ru K; Jia Y; Huang G; Xiao Z
    Oncotarget; 2017 Jan; 8(1):1603-1612. PubMed ID: 27906673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining metaphase cytogenetics with single nucleotide polymorphism arrays can improve the diagnostic yield and identify prognosis more precisely in myelodysplastic syndromes.
    Qin Y; Zhang H; Feng L; Wei H; Wu Y; Jiang C; Xu Z; Zhu H; Liu T
    Ann Med; 2022 Dec; 54(1):2627-2636. PubMed ID: 36148999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cytogenetics of myelodysplastic syndromes and its impact as prognostic factor].
    Borjas-Gutiérrez C; Domínguez-Cruz MD; González-García JR
    Rev Med Inst Mex Seguro Soc; 2017; 55(4):481-489. PubMed ID: 28591503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes.
    Nomdedeu M; Calvo X; Pereira A; Carrió A; Solé F; Luño E; Cervera J; Vallespí T; Muñoz C; Gómez C; Arias A; Such E; Sanz G; Grau J; Insunza A; Calasanz MJ; Ardanaz MT; Hernández-Rivas JM; Azaceta G; Álvarez S; Sánchez J; Martín ML; Bargay J; Gómez V; Cervero CJ; Allegue MJ; Collado R; Campo E; Esteve J; Nomdedeu B; Costa D;
    Genes Chromosomes Cancer; 2016 Apr; 55(4):322-7. PubMed ID: 26690722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, MDS): Guidelines from the groupe francophone de cytogénétique hématologique (GFCH).
    Auger N; Douet-Guilbert N; Quessada J; Theisen O; Lafage-Pochitaloff M; Troadec MB
    Curr Res Transl Med; 2023; 71(4):103409. PubMed ID: 38091642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
    Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
    Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group.
    Nomdedeu M; Pereira A; Calvo X; Colomer J; Sole F; Arias A; Gomez C; Luño E; Cervera J; Arnan M; Pomares H; Ramos F; Oiartzabal I; Espinet B; Pedro C; Arrizabalaga B; Blanco ML; Tormo M; Hernandez-Rivas JM; Díez-Campelo M; Ortega M; Valcárcel D; Cedena MT; Collado R; Grau J; Granada I; Sanz G; Campo E; Esteve J; Costa D;
    Leuk Res; 2017 Dec; 63():85-89. PubMed ID: 29121539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study on prognostic significances of different cytogenetic risk categories in patients with primary myelodysplastic syndromes].
    Qu SQ; Liu XP; Xu ZF; Zhang Y; Qin TJ; Zhang TJ; Cui R; Hao YS; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):819-24. PubMed ID: 22339954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updates in cytogenetics and molecular markers in MDS.
    Tiu RV; Visconte V; Traina F; Schwandt A; Maciejewski JP
    Curr Hematol Malig Rep; 2011 Jun; 6(2):126-35. PubMed ID: 21340513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
    Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J
    Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes.
    Solé F; Luño E; Sanzo C; Espinet B; Sanz GF; Cervera J; Calasanz MJ; Cigudosa JC; Millà F; Ribera JM; Bureo E; Marquez ML; Arranz E; Florensa L
    Haematologica; 2005 Sep; 90(9):1168-78. PubMed ID: 16154839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cytogenetic abnormalities of 50 MDS patients by FISH detection and conventional karyotype analysis].
    Gao DG; Li BT; Zhou LN; Chen H; Zhang B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1190-4. PubMed ID: 24156432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on cytogenetic and molecular changes in myelodysplastic syndromes.
    Schlegelberger B; Göhring G; Thol F; Heuser M
    Leuk Lymphoma; 2012 Apr; 53(4):525-36. PubMed ID: 21877899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelodysplastic Syndrome in Pakistan: Clinicohematological Characteristics, Cytogenetic Profile, and Risk Stratification.
    Mahmood R; Altaf C; Ahmed P; Khan SA; Malik HS
    Turk J Haematol; 2018 May; 35(2):109-115. PubMed ID: 28588002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies.
    Padron E; Steensma DP
    Curr Opin Hematol; 2015 Mar; 22(2):163-70. PubMed ID: 25575034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.